NanoFerrite particle based radioimmunonanoparticles: Binding affinity and in vivo pharmacokinetics

Engineering & Materials Science

• Pharmacokinetics 100%
• Nanoparticles 69%
• Iron oxides 57%
• Magnetic fields 30%
• Electrophoresis 22%
• Cellulose 19%
• Tumors 18%
• Heterografts 16%
• Tissue 14%
• Dextran 14%
• Surface charge 12%
• Charge density 12%
• Peptides 11%
• Polyethylene glycols 11%
• Liver 10%
• Heterojunction bipolar transistors 10%
• Toxicity 10%
• Assays 10%
• Surface morphology 9%
• Cells 8%
• Animals 8%
• Particle size 8%
• Blood 8%
• Imaging techniques 6%
• Heating 6%

Medicine & Life Sciences

• Nanoparticles 62%
• ferric oxide 55%
• Pharmacokinetics 53%
• ChL6 monoclonal antibody 38%
• Magnetic Field Therapy 29%
• Cellulose Acetate Electrophoresis 27%
• Immunoconjugates 23%
• Magnetic Fields 20%
• indium-111-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 15%
• Carbodiimides 13%
• Neoplasms 11%
• Dextrans 9%
• Heating 9%
• Particle Size 9%
• Nude Mice 8%
• Heterografts 7%
• Spleen 6%
• Monoclonal Antibodies 6%
• Lymph Nodes 6%
• Breast Neoplasms 5%
• Peptides 5%
• Kidney 4%
• Lung 4%
• Liver 4%
• Animals 4%
• In Vitro Techniques 3%
• Therapeutics 1%

Chemical Compounds

• Kd 53%
• Pharmacokinetics 53%
• Magnetic Field 52%
• Iron Oxide Nanoparticle 46%
• Nanoparticle 35%
• Iron Oxide 26%
• Electrophoresis 25%
• Acetate 19%
• Carbodiimide 15%
• Dextran 14%
• Charge Density 13%
• Dose 10%
• Surface 8%
• Time 5%